Gauss

Alphalisa pcsk9 kit 500 assay pts 500 Tests

Réf. UGAP : 3732408 Réf. Fournisseur : AL270C Réf. Constructeur : AL270C
Alphalisa pcsk9 kit 500 assay pts 500 Tests
Franco de port et d'emballage pour toutes les commandes supérieures à 80€ HT.

Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
La quantité choisie doit être comprise entre 1 et 999 999.
Il ne reste que 0 exemplaires.

Points clés

Alternative ELISA et WB, plus simple, plus rapide, très sensible, excellente gamme dynamique (5log), facilement miniaturisable / automatisable et peu onéreuse.

Formats: Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Features: No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia. AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

En savoir plus

Garantie

Garantie 0 Mois

Description

Alternative ELISA et WB, plus simple, plus rapide, très sensible, excellente gamme dynamique (5log), facilement miniaturisable / automatisable et peu onéreuse.

Formats: Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Features: No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia. AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Caractéristiques

Marque
REVVITY
Libellé produit fabricant
PCSK9 (human) AlphaLISA Detection Kit, 500 Assay Points
Référence distributeur
AL270C
Référence fabricant
AL270C
Fournisseur
REVVITY
Reprise en cas d’erreur client
non
Lieu de fabrication
États-Unis
Lieu de stockage
Pays-bas
Domaine de recherche
biologie cellulaire
Délai de péremption à la date de livraison
6 mois
Soumis à carboglace
oui
Soumis à réglementation
non
Température de conservation (°C)
+2 à +8 °C
Type d’application
quantification biomarqueur
Vendu par
500 tests
Quantité
N/A
Nomenclature Nacres
NA.84
Nomenclature CEA
SGP01
Nomenclature IRSN
273
Nomenclature INSERM
NA.NA84
Nomenclature CNRS
NA84
Nomenclature CHU
18.551
Nomenclature DGOS
LD11AOOO
Type d'échantillon
sérum, plasma, surnageant de culture cellulaire, tissu
Certification
RUO

Fournisseur